Data from GoldLS post
"2 2009343805 Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer AMDL, Inc. Small-Howard, Andrea 2009-03-30 LAPSED "
DCMAN What I find interesting is the patent elapsed with the current patent we let elapsed in the USA as well...If this is true data on the Australian patent from the messenger, then which patents did we apply with for the patent filed in September 2011? I believe it was a new Radient Patent and not the old one..It could be Radient and Provista's patent..Who knows...mb one of the skeptics can find out if you can have a patent elapse and then reapply with that same patent...If not..Then we have a new secret DR-0070 patent you understand..imo Wolf ahooololooooooooooo
Clearly this Proves that Radient has a Patent Pending in Australia...Wolfie
Radient Pharmaceuticals Files International Patents in Australia and New Zealand
Radient Pharmaceuticals Corporation September 14, 2011 7:00 AM
TUSTIN, CA--(Marketwire -09/14/11)- Radient Pharmaceuticals Corporation "the Company" or "Radient" (OTCQX: RXPC.PK - News) (Pinksheets: RXPC.PK - News), a developer and marketer of In Vitro Diagnostic (IVD) cancer tests, today announced it has filed for patent protection for its proprietary Onko-Sure® cancer test in Australia and New Zealand.
"Building an intellectual property position in foreign markets protects and supports sales of our proprietary Onko-Sure® cancer test globally. Both Australia and New Zealand have highly developed healthcare markets where we believe Onko-Sure® can add value as a minimally invasive, relatively low cost cancer diagnostic," stated Radient Chairman and CEO Douglas MacLellan.
The Onko-Sure® test kit is a 96-well ELISA test kit sold to clinical reference labs. Labs run individual tests prescribed by doctors. Blood samples can be run, in duplicate, for 40 people, on each test kit. Onko-Sure® is a non-invasive cancer blood test that has been shown, in a large body of published clinical research, to be effective in the detection of 19 different cancers.
